ArticleJournal of molecular histology2026
Modified citrus pectin modulates splenic immune responses and galectin expression following cisplatin treatment in Wistar rats.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modified citrus pectin (MCP), a polysaccharide from citrus fruits, modulates galectin-3 (Gal-3) and immune responses. Although MCP exhibits notable immunomodulatory effects, its role in drug-induced splenic and systemic toxicity remains unexplored. This study investigated the effects of MCP modulation on splenic immune remodeling and galectin expression in a rat model of cisplatin-induced toxicity. Wistar rats were divided into four groups (n = 5 animals/group): control (SHAM), MCP (100 mg/kg/day for 7 days), cisplatin (CIS, 10 mg/kg/day for 3 days), and MCP + CIS. Spleens were collected 6 h after the final cisplatin dose. Cisplatin induced splenic structural disorganization and selectively reduced nitric oxide levels without broadly affecting antioxidant enzymes. Cisplatin treatment was associated with increased CD3⁺ T cell labeling and enhanced tissue expression of Gal-1, -3, and - 9. MCP administration did not restore splenic architecture but promoted increased hemosiderin deposition in the red pulp, suggestive of enhanced erythrophagocytosis and altered iron handling, and markedly reduced CD3⁺ T cell immunoreactivity. MCP associated with cisplatin also reduced Gal-1 and Gal-3 levels and altered the relationship between galectins and splenic immune cell populations. Correlation analyses revealed positive associations between Gal-1, -3, and - 9 and CD68⁺ macrophages, as well as a selective association between Gal-3 and CD3⁺ T cells, exclusively in MCP + CIS animals. MCP does not mitigate cisplatin-induced splenic damage but alters immune cell distribution and galectin-related responses during cisplatin exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.